Overexpression of cathepsin B in gastric cancer identified by proteome analysis

Abstract We aimed to validate an analytical approach based on proteomics on gastric cancer specimens for the identification of new putative diagnostic or prognostic markers. Primary screening was performed on gastrectomy specimens obtained from ten consecutive patients with gastric cancer. Gastric epithelial cells were obtained with an epithelial cell enrichment technique, homogenized and then separated by two‐dimensional polyacrylamide gel electrophoresis (2‐D PAGE). The differential protein expression pattern was verified stepwise by Western blotting and immunohistochemistry on samples from 28 and 46 cancer patients, respectively. The putative clinical applicability and prognostic use were tested by an enzyme‐linked immunoabsorbent assay on serum samples obtained from 149 cancer patients. One hundred‐ninety‐one differentially expressed protein spots were found by 2‐D PAGE and identified by mass spectrometry, including cathepsin B, which was over‐expressed in six (60%) patients. Western blotting confirmed that the active form of cathepsin B is over‐expressed, while immunohistochemistry showed strong cytoplasmic staining in cancer tissues of 45 (98%) patients. The serum level of cathepsin B was increased in patients with gastric cancer compared to healthy controls ( P = 0.0026) and correlated with T‐category and the presence of distant metastases ( P < 0.05). Serum levels above 129 pmol·L −1 were associated with a reduced survival rate ( P = 0.0297). Proteome analysis is a valuable tool for the identification of prognostic markers in gastric cancer: Increased cathepsin B serum levels are associated with advanced tumor stages and progressive disease, which enables the classification of some gastric cancer patients into a subgroup that should undergo aggressive therapy.